Business News • PR NewsWire • Boston Biomedical Presents Clinical Data on First-in-Class Cancer Stemness Inhibitor Napabucasin at 2017 ASCO GI Symposium

Boston Biomedical Presents Clinical Data on First-in-Class Cancer Stemness Inhibitor Napabucasin at 2017 ASCO GI Symposium

Boston Biomedical Presents Clinical Data on First-in-Class Cancer Stemness Inhibitor Napabucasin at 2017 ASCO GI Symposium

CAMBRIDGE, Mass., Jan. 21, 2017 /PRNewswire/ -- Boston Biomedical, an industry leader in the development of novel compounds designed to target cancer stemness pathways, today presented data from two clinical studies for its lead investigational compound, napabucasin, at the 2017 American...

View More : http://www.prnewswire.com/news-releases/boston-biomedical-presents-clinical-data-on-first-in-class-cancer-stemness-inhib...

Releted News by prnewswire

It's Time Network Answers the Question: "What's Next?" Following Women's March on Washington

Sykes named Top 50 Kids Teacher by U.S. Kids Golf

La casa más cara de EE.UU. valorada en 250 millones de dólares

Guangzhou comienza evento itinerante internacional para el Fortune Global Forum (FGF) edición 2017